Recovery & repair
Thymosin Alpha-1
Tα1 · Zadaxin · 28-aa · immune
An immune-modulating peptide with genuine overseas clinical history (as Zadaxin) — but no UK licence, so it sits outside the standard prescription system here.
Reference status
Editorial research · independent review pending · 3 claims graded
What it is
Thymosin Alpha-1 is a naturally occurring thymic peptide that helps regulate T-cell immune responses. Under the brand Zadaxin it has been an approved medicine in several countries (mainly for chronic hepatitis B/C and as an immune adjunct in some cancer and vaccine settings).
It is not licensed in the UK or US. What's sold to the peptide community as a general 'immune balance' or inflammation product is a research chemical, not the regulated pharmaceutical, even though the molecule is identical.
The science, graded
What’s claimed — and how strong the evidence behind each claim actually is.
“Modulates immune response to infection”
Genuine clinical-trial history abroad, mainly for hepatitis and as a vaccine/immune adjunct.
Claim-level citation mapping is in progress.
“Reduces general inflammation and 'immune balance'”
A broader, vaguer claim than what the clinical trials actually tested.
Claim-level citation mapping is in progress.
“Interchangeable with the unlicensed research-grade product”
Same molecule, but sourcing, purity and quality control are not equivalent to a licensed medicine.
Claim-level citation mapping is in progress.
Legal and regulatory context
Separate summaries for Great Britain, the United States, and the European Union. These are preliminary research summaries awaiting independent regional review; they are not legal determinations or advice.
Great Britain
Licensed as a medicine in some countries but not in the UK — there is no NHS or private prescription route here. UK-available product is unlicensed and sold for research use only.
This is preliminary regulatory research, not a reviewed legal determination or legal advice.
United States
Regional legal and regulatory review required before publication.
This is preliminary regulatory research, not a reviewed legal determination or legal advice.
- FDA's Concerns About Unapproved Drugs · U.S. Food and Drug Administration
- Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks · U.S. Food and Drug Administration
European Union
Regional legal and regulatory review required before publication.
This is preliminary regulatory research, not a reviewed legal determination or legal advice.
- Buying medicines online · European Medicines Agency
What the community says
Discussed by the more research-literate corner of the community, often alongside general immune-support and longevity interest. Its genuine (if foreign) clinical pedigree makes it stand out from purely speculative peptides.
Where they’re talking
- r/PeptidesFrequently distinguished from purely experimental compounds due to Zadaxin history.
- Longevity forumsInterest as an immune-support candidate.
References
- 1.Supply unlicensed medicinal products (specials) · MHRA
- 2.FDA's Concerns About Unapproved Drugs · U.S. Food and Drug Administration
- 3.Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks · U.S. Food and Drug Administration
- 4.Buying medicines online · European Medicines Agency